Gilead Sciences (GILD) Aperçu de l'action
Gilead Sciences, Inc. est une société biopharmaceutique qui découvre, développe et commercialise des médicaments dans des domaines où les besoins médicaux ne sont pas satisfaits aux États-Unis, en Europe et dans le monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 4/6 |
| Performances passées | 6/6 |
| Santé financière | 4/6 |
| Dividendes | 5/6 |
GILD Community Fair Values
Create NarrativeSee what 217 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$128.38
FV
4.7% surévalué décote intrinsèque5.00%
Revenue growth p.a.
54
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Gilead Sciences, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$134.36 |
| Plus haut sur 52 semaines | US$157.29 |
| Plus bas sur 52 semaines | US$104.46 |
| Bêta | 0.33 |
| Variation sur 1 mois | 3.04% |
| Variation sur 3 mois | -8.67% |
| Variation sur 1 an | 23.16% |
| Variation sur 3 ans | 76.03% |
| Variation sur 5 ans | 105.70% |
| Évolution depuis l'introduction en bourse | 21,132.21% |
Nouvelles et mises à jour récentes
Seeking Alpha • May 21
Why Gilead Sciences Is Now A Hold (Rating Upgrade)
Summary Gilead Sciences, Inc. once again demonstrated strong performance of Trodelvy, Livdelzi, and Yeztugo. This "trio" generated $701 million in revenue for Gilead in Q1, up 110.5% quarter-on-quarter. However, Gilead's cell therapy franchise is once again struggling, with sales of Yescarta and Tecartus falling 12.3% YoY. Moreover, I still believe that GILD's acquisition of anito-cel was a mistake, given that J&J/Legend's Carvykti is becoming the "gold standard" for the treatment of R/R multiple myeloma. Further in this article, you'll learn why, in my view, GILD's risk/reward has become balanced. Read the full article on Seeking Alpha
Nouveau récit • May 19
Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase
Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.Recent updates
Seeking Alpha • May 21
Why Gilead Sciences Is Now A Hold (Rating Upgrade)
Summary Gilead Sciences, Inc. once again demonstrated strong performance of Trodelvy, Livdelzi, and Yeztugo. This "trio" generated $701 million in revenue for Gilead in Q1, up 110.5% quarter-on-quarter. However, Gilead's cell therapy franchise is once again struggling, with sales of Yescarta and Tecartus falling 12.3% YoY. Moreover, I still believe that GILD's acquisition of anito-cel was a mistake, given that J&J/Legend's Carvykti is becoming the "gold standard" for the treatment of R/R multiple myeloma. Further in this article, you'll learn why, in my view, GILD's risk/reward has become balanced. Read the full article on Seeking AlphaNouveau récit • May 19
Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase
Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.
Mise à jour du récit • May 01
GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions
Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.
Mise à jour du récit • Apr 17
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.Mise à jour du récit • Apr 03
GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.
Mise à jour du récit • Mar 20
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.Mise à jour du récit • Mar 05
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.Mise à jour du récit • Feb 19
GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.Mise à jour du récit • Feb 05
GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.Mise à jour du récit • Jan 22
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.Mise à jour du récit • Jan 07
GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.Mise à jour du récit • Dec 20
GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.Mise à jour du récit • Dec 06
GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.Mise à jour du récit • Nov 22
GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.Mise à jour du récit • Nov 08
GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.Mise à jour du récit • Oct 25
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.Mise à jour du récit • Oct 10
Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.Mise à jour du récit • Sep 04
Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.Article d’analyse • Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Apr 25
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Summary Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest performer, with Biktarvi leading the charge, while oncology investments have yet to yield significant returns. Key upcoming milestones include the FDA decision on lenacapavir, a potential blockbuster HIV therapy, and various oncology and cell therapy data readouts. Despite recent share price growth, I am downgrading GILD stock to "Hold" due to concerns over oncology and cell therapy prospects and limited upside potential. Read the full article on Seeking AlphaNouveau récit • Apr 08
New HIV, Livdelzi And CAR T Options Will Expand Reach
Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.Rendement pour les actionnaires
| GILD | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 3.0% | 3.1% | 1.2% |
| 1Y | 23.2% | 34.6% | 28.7% |
Rendement vs Industrie: GILD a sous-performé le secteur US Biotechs qui a rapporté 34.6 % au cours de l'année écoulée.
Rendement vs marché: GILD a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: GILD n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de GILD ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1987 | 17,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc. est une société biopharmaceutique qui découvre, développe et commercialise des médicaments dans des domaines où les besoins médicaux ne sont pas satisfaits aux États-Unis, en Europe et dans le monde. La société propose Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza et Yeztugo pour le traitement de l'infection par le VIH-1 chez les patients. Elle propose également Epclusa, Livdelzi et Vemlidy pour le traitement du virus de l'hépatite C chronique, de la cholangite biliaire primitive et du virus de l'hépatite B chronique ; Tecartus, une thérapie cellulaire T pour le traitement des patients adultes ; Trodelvy, une injection pour usage intraveineux ; et Yescarta, une suspension pour perfusion intraveineuse, est une thérapie cellulaire CAR T pour le traitement des patients adultes.
Gilead Sciences, Inc. Résumé des fondamentaux
| GILD statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$166.82b |
| Bénéfices(TTM) | US$9.22b |
| Recettes(TTM) | US$29.74b |
18.1x
Ratio P/E5.6x
Ratio P/SLe site GILD est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| GILD compte de résultat (TTM) | |
|---|---|
| Recettes | US$29.74b |
| Coût des recettes | US$6.14b |
| Marge brute | US$23.60b |
| Autres dépenses | US$14.39b |
| Les revenus | US$9.22b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 7.42 |
| Marge brute | 79.37% |
| Marge bénéficiaire nette | 30.99% |
| Ratio dettes/capitaux propres | 94.6% |
Quelles ont été les performances à long terme de GILD?
Voir les performances historiques et les comparaisonsDividendes
2.4%
Rendement actuel des dividendes43%
Ratio de distributionLe site GILD verse-t-il des dividendes fiables ?
Voir GILD l'historique des dividendes et les indices de référence| Gilead Sciences dates des dividendes | |
|---|---|
| Date ex-dividende | Jun 15 2026 |
| Date de paiement du dividende | Jun 29 2026 |
| Jours jusqu'au dividende Ex | 19 days |
| Jours jusqu'à la date de paiement du dividende | 33 days |
Le site GILD verse-t-il des dividendes fiables ?
Voir GILD l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 14:59 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Gilead Sciences, Inc. est couverte par 66 analystes. 25 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |